Page 13 - Indian Pharma Companies
Aurobindo Q1 profit up 39.5% at Rs 636 crore on strong revenue growth
Revenue from operations rose 28.1% year-on-year to Rs 5,444.6 crore during the quarter under review
 "Aurobindo Q1 profit up 39.5% at Rs 636 crore on strong revenue growth")
India's new drug nods from US dip in Q1 due to increased scrutiny on firms
India's share of ANDA approvals given by the US Food and Drug Administration (USFDA), too, has fallen from 43 per cent in fourth quarter (Q4) of 2018-19 (FY19) to 33 per cent in Q1FY20
 "India's new drug nods from US dip in Q1 due to increased scrutiny on firms")
Pharma funds remain in poor health amid headwinds on compliance
The BSE Healthcare Index has fallen 10 per cent in the last one year
What's bugging Indian, Chinese medicine companies making crucial heart drug
US inspectors cite Cadila Healthcare and Alkem Laboratories--both makers of valsartan--for quality-control failures.
 "What's bugging Indian, Chinese medicine companies making crucial heart drug")
Charticle: How Jan Aushadhi stores are disrupting the Indian pharma market
Analysts point out that growth from product introductions has nearly halved over the last two years as the drug regulator has been more stringent about new combination drugs
 "Charticle: How Jan Aushadhi stores are disrupting the Indian pharma market")
Jan Aushadhi scheme may disrupt 20% of Indian pharma market sales: Report
India has over 5,000 Jan Aushadhi stores that cover a list of 800 plus drugs, both chronic and acute
 "Jan Aushadhi scheme may disrupt 20% of Indian pharma market sales: Report")
Cold wave across US to bring big business for Indian drug companies
There have been 20.4 million to 23.6 million flu illnesses in the US between October 1, 2018, and February 23, 2019
Indian pharma to hit double-digit growth on US sales, weak rupee: CRISIL
As per Crisil, green shoots are already visible in the first quarter for 20 of these listed drug-makers
 "Indian pharma to hit double-digit growth on US sales, weak rupee: CRISIL")
Warning letters to Indian pharma companies from US FDA declining: Study
The number of cases of data integrity violations too is showing a decline, says study by IPA and consultancy firm McKinsey
 "Warning letters to Indian pharma companies from US FDA declining: Study")
Indian pharma sees traction in novel biologics
While Glenmark is betting on its biologic for atorpic dermatitis, Biocon was the first to develop and introduce two novel biologics in the Indian market
 "Indian pharma sees traction in novel biologics")
Competition takes shine off niche pharma products
Aurobindo has been able to partially buck the trend; analysts expect prospects of most players to improve in second half of FY19
 "Competition takes shine off niche pharma products")